This article is part of Ophthalmology Advisor’s Focus on Retina coverage from the 2021 meeting of the American Academy of Ophthalmology, held in New Orleans from November 12 to 15, 2021. The team at Ophthalmology Advisor will be reporting on a variety of the research presented by the retinal experts at the AAO. Check back for more from the AAO 2021 Meeting.
Suprachoroidal injections (SCI) of triamcinolone acetonide (CLS-TA) can reduce central subfield thickness (CST) and improve best corrected visual acuity (BCVA) for patients with macular edema secondary to noninfectious uveitis, according to researchers. The results of the phase 3 PEACHTREE trial (ClinicalTrials.gov Identifier: NCT02595398) were presented at the American Academy of Ophthalmology 2021 meeting, held in New Orleans, November 12-15.
Researchers compared outcomes in unrescued individuals who received SCI of CLS-TA with rescued control individuals diagnosed with uveitic macular edema. The individuals were assigned to receive SCI CLS-TA or sham treatment. Patients received the treatment and repeated it 12 weeks after baseline. Rescue therapy was available as needed.
Unrescued CLS-TA individuals gained significantly more BCVA overall (mean 15.7 letters) compared with rescued control individuals (mean 10.9 letters P =.080). The unrescued CLS-TA group experienced a significantly greater reduction, on average, of CST compared with the control group individuals (174.0 µm vs. 148.5 µm; P =.040).
The unrescued CLS-TA group gained at least 15 letters in BCVA compared with 37% of rescued control individuals (P =.115).
The investigators reported that 13.5% of patients who underwent CLS-TA received rescue therapy compared with 71.8% of control individuals. Surgical interventions were not needed for intraocular pressure, the researchers reported.
Henry CR, Ciulla TA. Post hoc analysis of suprachoroidal CLS-TA vs. rescue therapies in macular edema associated with noninfectious uveitis. Poster presented at: The American Academy of Ophthalmology 2021 Annual Meeting. New Orleans. Abstract PO111.